ClinicalTrials.gg

Program

anitocabtagene autoleucel

Also written as “Anitocabtagene Autoleucel”, “anitocabtagene-autoleucel” and “anito-cel”.

Its studies are mostly in Multiple Myeloma · Muscle Weakness, led by Gilead Sciences.

Furthest: phase 3, since May 9, 20246 company-led studies, 6 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences66 open or runningphase 3since May 9, 2024Oct 17, 2019Dec 2026phase 2 · NCT05396885

Also a collaborator on its studies: Arcellx.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 17, 2019First study: phase 1 study in RecurrenceFirst studyNCT04155749 · 40 enrolled · United States
  2. May 12, 2022Phase 2 study in Multiple MyelomaNCT05396885 · 136 enrolled · United States
  3. May 9, 2024Phase 3 study in Multiple MyelomaNCT06413498 · 452 enrolled · United States, Australia, Austria and more
  4. Sep 19, 2024Phase 1 study in Muscular DiseasesNCT06626919 · 30 planned · United States
  5. Oct 14, 20262 phase 3 studies in Multiple MyelomaNCT07903506, NCT07887672
  6. Oct 22, 2026Primary completion moved from 2027-03 to 2028-10Date moved laterphase 1 · +19 months · NCT06626919

Ahead

  1. Dec 2026Primary completion: phase 2 study in Multiple MyelomaNCT05396885
  2. Jul 2028Primary completion: phase 3 study in Multiple MyelomaNCT06413498
  3. Oct 2028Primary completion: phase 1 study in Muscular DiseasesNCT06626919
  4. Mar 2039Primary completion: phase 3 study in Multiple MyelomaNCT07903506

TargetBeta

TNFRSF17 →read by rule
“A preparation of autologous T-lymphocytes that are genetically modified ex vivo and transduced with a lentiviral vector to express a D-binding domain based chimeric antigen receptor (CAR) that specifically recognizes the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA; tumor necrosis ”NCIt, by rule

Other programs on TNFRSF17

ProgramCompanyFurthest phaseStudies
elranatamabrulePfizerphase 415
linvoseltamabruleRegeneron Pharmaceuticalsphase 413
teclistamabruleJohnson & Johnsonphase 411
belantamab mafodotinruleGlaxoSmithKlinephase 325
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
etentamigAbbViephase 311
ramantamigJohnson & Johnsonphase 37
equecabtagene autoleucelrulenanjing-iaso-biotechnology-co-ltdphase 35
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
Evarucabgene Autoleucelrulenexcella-incphase 32
Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytesrulecartesian-therapeuticsphase 26

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07903506Multiple Myeloma3Not yet recruitingMar 2039750
NCT07887672Multiple Myeloma3Not yet recruitingFeb 2042600
NCT06626919Muscular Diseases · United States1RecruitingOct 202830
NCT06413498Multiple Myeloma · United States, Australia, Austria and more3Active, not recruitingJul 2028452
NCT05396885Multiple Myeloma · United States2Active, not recruitingDec 2026136
NCT04155749Recurrence · United States1Active, not recruitingOct 3, 202440

How it is read

Names in the registry

  • “Anitocabtagene Autoleucel”, 2 entries
  • “anitocabtagene-autoleucel”, 2 entries
  • “anito-cel”, 1 entry
  • “Anitocabtagene autoleucel”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.